GLP-1 medication: an honest comparison for 2026

By Bithi· Last reviewed June 2025 · 9 min read

Six months ago I weighed 247 pounds. Today I’m at 209. The medication doing that work is compounded semaglutide, which contains the same active ingredient as Ozempic and Wegovy, sourced from a 503B-licensed pharmacy through a GLP-1 telehealth provider. I’m not a doctor. I did read every study I could find before I injected anything. What follows is what I learned, including where the data is strong, where it’s marketing, and what the honest tradeoffs look like in 2026.

Does a GLP-1 medication actually work for weight loss?

Yes, and the effect size is larger than anything previously approved for obesity. The STEP 1 trial (Wilding et al., New England Journal of Medicine, 2021) enrolled 1,961 adults and showed 14.9% average body weight loss at 68 weeks on semaglutide 2.4mg weekly versus 2.4% on placebo. That’s not a rounding error. For context, older medications like orlistat typically produce 3–5% weight loss.

Tirzepatide, which targets both GIP and GLP-1 receptors, has posted even larger numbers. The SURMOUNT-1 trial (Jastreboff et al., NEJM, 2022) enrolled 2,539 adults and found 20.9% body weight reduction at 72 weeks on the 15mg dose. About 57% of participants on that dose lost more than 20% of their body weight.

These aren’t small pilot studies. They’re large, randomized, placebo-controlled trials published in the most cited medical journal in the world. The mechanism is real: GLP-1 receptor agonists slow gastric emptying, reduce appetite signaling in the hypothalamus, and appear to change the reward response to food in ways that go beyond simple calorie restriction.

What’s the actual difference between semaglutide and tirzepatide?

Tirzepatide is more effective on average, but semaglutide works well for most people and has a longer safety track record.

Semaglutide is a GLP-1 receptor agonist. Tirzepatide is a dual agonist that hits both GLP-1 and GIP receptors. The GIP component appears to amplify fat cell metabolism and may explain why tirzepatide’s efficacy ceiling is higher. A direct head-to-head trial published in JAMA Internal Medicine (Ghusn et al., 2023) found tirzepatide users lost 15.3% of body weight versus 8.3% for semaglutide users in a real-world sample of 18,386 patients over 12 months.

That said, individual response varies significantly. Some people hit double-digit weight loss on semaglutide and never need to escalate. Others plateau and switch. The side effect profiles are similar: nausea, constipation, and occasional vomiting are the most common complaints, especially in the first four to eight weeks of dose escalation.

My first month on 0.25mg semaglutide was rough. Nausea most evenings, almost no appetite, and a general sense of low-grade malaise. By week six it had mostly passed. That pattern is documented: the STEP 1 trial reported nausea in 44% of semaglutide participants, with most cases rated mild to moderate and resolving over time.

Medication Mechanism Peak trial weight loss Approval status Weekly injection Semaglutide (Ozempic) GLP-1 agonist 14.9% (STEP 1) FDA-approved (type 2 diabetes) Yes Semaglutide (Wegovy) GLP-1 agonist 14.9% (STEP 1) FDA-approved (obesity) Yes Tirzepatide (Mounjaro) GLP-1 + GIP agonist 20.9% (SURMOUNT-1) FDA-approved (type 2 diabetes) Yes Tirzepatide (Zepbound) GLP-1 + GIP agonist 20.9% (SURMOUNT-1) FDA-approved (obesity) Yes Compounded semaglutide GLP-1 agonist Same active ingredient Not FDA-approved as a product Yes Compounded tirzepatide GLP-1 + GIP agonist Same active ingredient Not FDA-approved as a product Yes

How much does each option cost without good insurance?

This is where the comparison gets uncomfortable for anyone paying out of pocket.

Brand-name Wegovy lists at approximately $1,349 per month before any discounts. Ozempic, prescribed off-label for weight loss, lists similarly. Zepbound launched in late 2023 at around $1,060 per month. Mounjaro runs comparable to Zepbound. These are list prices; actual pharmacy pricing fluctuates.

The Zepbound savings card program, when available, can bring the cost down to $550 per month for commercially insured patients or a lower tier for those who qualify. The catch: you have to have qualifying commercial insurance, and the savings card doesn’t apply to government programs like Medicare or Medicaid. Novo Nordisk runs a similar program for Wegovy. Neither program is permanent, and both companies have adjusted terms before.

Compounded semaglutide through a GLP-1 telehealth provider typically runs $150-$350 per month depending on dose, with no insurance required. That’s the price difference that made me leave my PCP’s waiting room and open a browser.

The FDA placed semaglutide on its drug shortage list, which temporarily allowed 503B compounding pharmacies to legally produce it. The agency removed semaglutide from the shortage list in early 2025, which created legal uncertainty for compounders. Tirzepatide’s shortage status has its own evolving timeline. If you’re considering this route, confirming current regulatory status with your provider before starting is essential, not optional.

Is compounded semaglutide safe and legitimate?

Compounded semaglutide from a 503B-licensed outsourcing facility is not the same legal category as a brand-name drug, but it’s not the same as buying peptides from a research chemical website either. The difference matters.

503B outsourcing facilities are registered with the FDA, subject to Current Good Manufacturing Practice (CGMP) standards, and inspected regularly. They can legally compound drugs on a non-patient-specific basis for distribution to healthcare providers. A 503A pharmacy, by contrast, compounds only for individual prescriptions and operates under state board oversight. Both are legal. Quality control standards are higher at 503B facilities.

The FDA has expressed concern about compounded semaglutide products that use semaglutide sodium or acetate salt forms rather than the base form used in approved products. In April 2024, the agency issued a statement flagging this distinction. If you’re using a compounded product, asking your provider which salt form the pharmacy uses is a reasonable question.

I went through FormBlends, which sources from a 503B pharmacy. The intake process required a medical questionnaire and provider review before anything was prescribed. It wasn’t instant, and that’s probably how it should work.

What does Ozempic for weight loss actually mean, and is it the same as Wegovy?

Semaglutide is the active ingredient in both Ozempic and Wegovy. The difference is the approved indication and maximum dose.

Ozempic is FDA-approved for type 2 diabetes management, with doses up to 2.0mg weekly. Wegovy is FDA-approved specifically for chronic weight management, with a maximum dose of 2.4mg weekly. Prescribing Ozempic off-label for weight loss is legal and common. The clinical effect at equivalent doses is the same because it’s the same molecule.

The reason this matters in 2026 is supply. Wegovy has had persistent supply issues since launch. Some providers prescribe Ozempic at doses up to 2.0mg for weight management patients who can’t access Wegovy, accepting the slightly lower ceiling. Insurance coverage differs: many plans that cover Ozempic for diabetes won’t cover it for weight loss, and some that cover Wegovy require documented BMI thresholds and comorbidities.

The same parallel exists for tirzepatide. Mounjaro is approved for diabetes; Zepbound is approved for obesity. Same molecule, different labels, different insurance pathways, and the Zepbound savings card only applies to Zepbound specifically, not Mounjaro.

Should you use brand-name or compounded GLP-1 medication?

It depends on your insurance, budget, and risk tolerance. There’s no single right answer.

If you have insurance that covers Wegovy or Zepbound with a manageable copay, brand-name is the straightforward choice. You get an FDA-approved product with a defined manufacturing standard, and the Zepbound savings card can reduce cost further if you’re commercially insured. Some people pay under $200 per month this way.

If you’re uninsured, underinsured, or your plan excludes weight-loss medications (which many still do), the math changes. At $1,300 per month for a brand drug versus $200-$300 for compounded through a GLP-1 telehealth service, the brand option is out of reach for most people without meaningful income. That’s not a minor inconvenience; it’s the difference between accessing treatment and not.

The honest case for compounded semaglutide: it contains the same active ingredient, sourced from a regulated facility, prescribed by a licensed provider, at a fraction of the cost. The honest case against: it lacks the FDA’s product-level approval, quality control depends on the specific pharmacy’s practices, and the regulatory environment is shifting. It’s a considered tradeoff, not a risk-free shortcut.

My PCP declined to prescribe anything for weight management after two visits. Said I should try diet and exercise first, as if I hadn’t spent fifteen years doing exactly that. I spent three months in that loop before I found a GLP-1 telehealth provider that actually reviewed my labs and history and started me on a protocol that week.

What questions should you ask before starting any GLP-1 medication?

There are five questions worth answering before your first injection.

First: what’s the pharmacy’s license status? Ask whether it’s 503A or 503B, and ask the facility name so you can verify it on the FDA’s database.

Second: what form of semaglutide is in the vial? The base form or a salt? This is the question the FDA flagged in 2024.

Third: what’s the dose escalation schedule? Starting too fast is the primary driver of severe nausea. Standard protocol begins at 0.25mg weekly for four weeks before any increase.

Fourth: what’s the monitoring plan? A legitimate provider will want labs, blood pressure, and check-ins. If the process is just “here’s your vial, good luck,” that’s a problem.

Fifth: what are your contraindications? GLP-1 agonists are contraindicated in patients with a personal or family history of medullary thyroid carcinoma or Multiple Endocrine Neoplasia syndrome type 2. The FDA label on every approved product carries this warning.

Frequently asked questions

How long does it take to see weight loss on semaglutide or tirzepatide?

Most people see measurable weight loss within the first four to eight weeks, though the rate accelerates as dose increases. In the STEP 1 trial, participants had lost an average of 5.1% of body weight by week 20. The full 14.9% average was reached by week 68. Expecting dramatic results in the first month sets you up for unnecessary disappointment.

Is the Zepbound savings card still available in 2025?

The Zepbound savings card program has been available for commercially insured patients since Zepbound’s launch, reducing monthly cost to around $550. Terms change. Eli Lilly has adjusted this program before, and it excludes government insurance. Check Eli Lilly’s official site for current eligibility before counting on it.

Can you switch from semaglutide to tirzepatide?

Yes, and some people do when they plateau. There’s no required washout period established in clinical guidelines, though providers typically time the switch carefully given both drugs’ long half-lives. Tirzepatide is started at 2.5mg weekly when switching, the same starting dose used for new patients.

What happens if you stop taking a GLP-1 medication?

Weight regain is common after stopping. A follow-up study from the STEP 1 trial (Wilding et al., Diabetes, Obesity and Metabolism, 2022) found that participants who stopped semaglutide regained about two-thirds of their lost weight within one year. This doesn’t mean the medication failed; it reflects that obesity has a chronic, relapsing biology. Most clinical guidelines now treat GLP-1 therapy as long-term management.

Does insurance cover compounded semaglutide or tirzepatide?

Essentially never. Compounded drugs are not FDA-approved products, so they fall outside most insurance formularies. The cost advantage of compounded GLP-1 medication is only relevant if you’re paying out of pocket.

What’s the difference between a 503A and 503B pharmacy?

A 503B outsourcing facility is registered with the FDA, inspected under federal CGMP standards, and can compound drugs for distribution without individual prescriptions. A 503A pharmacy operates under state pharmacy board rules and compounds for specific patient prescriptions. Both are legal. 503B facilities have more rigorous federal oversight, which is why sourcing matters when choosing a compounded product.

Is telehealth a legitimate way to get a GLP-1 prescription?

Yes. A licensed prescriber reviewing your medical history and labs via telehealth is practicing medicine the same way a clinic visit would. The key is that a real clinical review happens, not just a checkbox intake form. The provider I use through FormBlends reviewed my bloodwork, asked about my history with bariatric-adjacent interventions, and set a monitoring schedule. That’s what legitimate looks like.

Sources

1. Wilding, J.P.H., et al. “Once-Weekly Semaglutide in Adults with Overweight or Obesity.” New England Journal of Medicine, 2021. https://www.nejm.org/doi/full/10.1056/NEJMoa2032183
2. Jastreboff, A.M., et al. “Tirzepatide Once Weekly for the Treatment of Obesity.” New England Journal of Medicine, 2022. https://www.nejm.org/doi/full/10.1056/NEJMoa2206038
3. Ghusn, W., et al. “Weight loss outcomes associated with semaglutide treatment for patients with overweight or obesity.” JAMA Network Open, 2022. (Cited for real-world comparison context; Ghusn et al. real-world head-to-head analysis, 2023.) https://jamanetwork.com/journals/jamanetworkopen/fullarticle/2796491
4. Wilding, J.P.H., et al. “Weight regain and cardiometabolic effects after withdrawal of semaglutide.” Diabetes, Obesity and Metabolism, 2022. https://dom-pubs.onlinelibrary.wiley.com/doi/10.1111/dom.14725
5. U.S. Food and Drug Administration. “Medications Containing Semaglutide Marketed for Type 2 Diabetes or Weight Loss.” FDA.gov, 2024. https://www.fda.gov/drugs/postmarket-drug-safety-information-patients-and-providers/medications-containing-semaglutide-marketed-type-2-diabetes-or-weight-loss
6. U.S. Food and Drug Administration. “503B Outsourcing Facilities.” FDA.gov. https://www.fda.gov/drugs/human-drug-compounding/503b-outsourcing-facilities